Introduction

Merrion has a portfolio of unique patented oral drug delivery technologies, including the Gastrointestinal Permeation Enhancement Technology (GIPET™) and the Gastrointestinal Retention System (GIRES™). We make these available to partner pharmaceutical companies through strategic licensing agreements.

The Merrion team:

Has the skills and experience to develop new oral medicines.
Have state of the art facilities in Dublin, Ireland, which are licensed for clinical trial manufacture.
Can take a project from feasibility to final formulation in an innovative, rapid and cost effective process.
Have the communication skills and personal flexibility to make partnerships work.

GIPET™ provides a unique solution by:

Providing substantially increased oral bioavailability to a wide variety of drug molecules, from conventional small molecules to larger biotech molecules such as peptides, pentasaacharides, Antisense oligonucleotides and several others.
Being supported by a large clinical database, encompassing over 20 clinical trials and a large body of other data.
Having 3 distinct patented technology approaches ( GIPET I, II, III) gives greater likelihood of success, and options for development.
GIPET I, II are GRAS (Generally Regarded As Safe) allowing rapid development with increased likelihood of success.
Rapid, cost effective and validated screening model to evaluate the technologies.

GIRES™ provides a unique solution by:

Extended gastric retention - 16 -24 hours in clinical trials – with potential for extended drug release.
Presence of food enhances retention.